Aridis Pharmaceuticals, Inc. (ARDS)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2022 | 1.29 Million USD | -75.54% |
| 2021 | 5.28 Million USD | 1813.77% |
| 2020 | 276 Thousand USD | 0.0% |
| 2019 | - USD | 0.0% |
| 2018 | - USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 Q1 | 1.14 Million USD | -11.15% |
| 2023 Q3 | 854 Thousand USD | -14.77% |
| 2023 Q2 | 1 Million USD | -12.72% |
| 2022 FY | 1.29 Million USD | -75.54% |
| 2022 Q3 | 4.92 Million USD | -60.52% |
| 2022 Q4 | 1.29 Million USD | -73.79% |
| 2022 Q1 | 12.35 Million USD | 133.96% |
| 2022 Q2 | 12.48 Million USD | 1.04% |
| 2021 Q2 | - USD | -100.0% |
| 2021 FY | 5.28 Million USD | 1813.77% |
| 2021 Q3 | - USD | 0.0% |
| 2021 Q4 | 5.28 Million USD | 0.0% |
| 2021 Q1 | 110 Thousand USD | -60.14% |
| 2020 Q4 | 276 Thousand USD | -23.12% |
| 2020 Q3 | 359 Thousand USD | -18.04% |
| 2020 Q2 | 438 Thousand USD | 0.0% |
| 2020 Q1 | - USD | 0.0% |
| 2020 FY | 276 Thousand USD | 0.0% |
| 2019 FY | - USD | 0.0% |
| 2019 Q4 | - USD | 0.0% |
| 2019 Q3 | - USD | 0.0% |
| 2019 Q2 | - USD | 0.0% |
| 2019 Q1 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| America Great Health | 1.12 Million USD | -15.035% |
| Ampio Pharmaceuticals, Inc. | - USD | -Infinity% |
| Biora Therapeutics, Inc. | 43.73 Million USD | 97.046% |
| Bio-Path Holdings, Inc. | 10 Thousand USD | -12820.0% |
| Better Therapeutics, Inc. | 10.34 Million USD | 87.514% |
| Calithera Biosciences, Inc. | 136 Thousand USD | -850.0% |
| Comera Life Sciences Holdings, Inc. | 120.3 Thousand USD | -973.964% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | - USD | -Infinity% |
| Eloxx Pharmaceuticals, Inc. | 8.69 Million USD | 85.136% |
| Evelo Biosciences, Inc. | 48.87 Million USD | 97.357% |
| Evolutionary Genomics, Inc. | 3.74 Million USD | 65.489% |
| Finch Therapeutics Group, Inc. | 28.4 Million USD | 95.451% |
| Galera Therapeutics, Inc. | 151.04 Million USD | 99.145% |
| Innovation1 Biotech Inc. | 218.99 Thousand USD | -489.957% |
| Kiromic BioPharma, Inc. | 911.5 Thousand USD | -41.744% |
| Molecular Templates, Inc. | 9.74 Million USD | 86.738% |
| Navidea Biopharmaceuticals, Inc. | 1.87 Million USD | 30.972% |
| NexImmune, Inc. | - USD | -Infinity% |
| Orgenesis Inc. | 19.06 Million USD | 93.224% |
| Panbela Therapeutics, Inc. | 4.19 Million USD | 69.194% |
| Point of Care Nano-Technology, Inc. | - USD | -Infinity% |
| PaxMedica, Inc. Common Stock | - USD | -Infinity% |
| Scopus BioPharma Inc. | - USD | -Infinity% |
| Sorrento Therapeutics, Inc. | 104.33 Million USD | 98.762% |
| Statera Biopharma, Inc. | 11.43 Million USD | 88.698% |
| TRACON Pharmaceuticals, Inc. | 732 Thousand USD | -76.503% |
| Trevena, Inc. | 35.23 Million USD | 96.333% |
| Vaxxinity, Inc. | 13.26 Million USD | 90.258% |
| Vaccinex, Inc. | 26 Thousand USD | -4869.231% |
| Vicapsys Life Sciences, Inc. | - USD | -Infinity% |
| Viracta Therapeutics, Inc. | - USD | -Infinity% |
| ZIVO Bioscience, Inc. | - USD | -Infinity% |